In a Phase 1 clinical trial we demonstrated progressive removal of amyloid with up to three cycles of a therapy that targetted the plasma protein serum amyloid P component (SAP), which is universally present in amyloid deposits, and is therefore a target in all forms of amyloidosis [9]. The gene discussed is APCS; the disease is amyloidosis.